PMPRB

Various amendments relating to the Patented Medicines Prices Review Board are to come into force on June 30, 2021 including amendments to sections 79 to 103 of the Patent Act. In addition there are some changes being made for consistency with the Patent Act and to encompass CSPs. This is in addition to the amended Patented Medicines Regulations expanding reporting requirements are scheduled to come into force July 1, 2021 after being delayed several times. Continue reading PMPRB

Federal Court of Appeal

The Federal Court of Appeal, in a new Practice Notice “Electronic Service of Documents for the duration of the Suspension Period”, makes electronic service by email permissible in all cases and requires email addresses be added to all documents filed with the Federal Court of Appeal, with limited exceptions, while the, now indefinite, Suspension Period is in effect.

Continue reading Federal Court of Appeal

Federal Court

The Federal Court has published revised consolidated intellectual property guidance for case management and trial management. The Court has included a blackline version which indicates that changes include limiting “second round” discovery, use of claim charts, compendia and slide decks at trial and requests to admit.

Trademark Backlog

CIPO has published two practice notices directed to the backlog of trademarks awaiting examination:

  • Requests for expedited examination – “effective immediately the Office will begin accepting requests for expedited examination of trademark applications” on the basis of court proceedings, combating counterfeit products, protect marks on online marketplaces, or to preserve claims of priority.
  • Measures to improve timeliness in examination – the Office will prioritize applications with statements of goods or services selected from the pre-approved list, issue fewer examination reports prior to refusal, and will provide fewer examples of goods or services that would be acceptable in reports.

Continue reading Trademark Backlog

PM(NOC)

Proposed amendments to the Patented Medicines (Notice of Compliance) Regulations have been published for consultation in the Canada Gazette to expand the definition of a “claim for medicinial ingredient” to include salts so that “the scope of protection under the Regulations corresponds to the type of activities contemplated under the proposed amendments to the [Food and Drug Regulations]”. Continue reading PM(NOC)

Canadian Intellectual Property